Mipsagargin is a recent generic drug that was created by GenSpera, Inc., a leader in developing therapies for cancer treatments.
This is a new drug that contains a natural product (a poisonous weed) that kills the growth of tumors.
Currently, Mipsagargin is in phase two clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer).
Will this drug be expanding to other cancer treatments?
Dr. Craig Dionne shares what Mipsagargin is and how patients can receive this drug for treatment.
Mipsagargin: Promise of a New Cancer Treatment
Featured Speaker:
Dr. Craig Dionne has more than 25 years of experience in the pharmaceutical industry, directing drug discovery and drug development.
As chief executive officer at GenSpera, Dr. Dionne directs the organization as a clinical stage pharmaceutical company and its current work developing cutting-edge therapeutics to treat some of the most challenging areas in oncology and urology.
Prior to launching GenSpera in 2003, he served as executive vice president of research and therapeutics at the Prostate Cancer Foundation. As a senior vice president in Discovery Research at Cephalon, Inc., his efforts were instrumental in identifying four different drugs that were brought into clinical evaluation over a span of six years.
Dr. Dionne received his doctorate from the University of Texas in 1984 and trained as a postdoctoral fellow at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Dionne is co-inventor on six issued United States patents and has co-authored more than 50 scientific publications.
Dr. Craig Dionne has more than 25 years of experience in the pharmaceutical industry, directing drug discovery and drug development.As chief executive officer at GenSpera, Dr. Dionne directs the organization as a clinical stage pharmaceutical company and its current work developing cutting-edge therapeutics to treat some of the most challenging areas in oncology and urology.
Prior to launching GenSpera in 2003, he served as executive vice president of research and therapeutics at the Prostate Cancer Foundation. As a senior vice president in Discovery Research at Cephalon, Inc., his efforts were instrumental in identifying four different drugs that were brought into clinical evaluation over a span of six years.
Dr. Dionne received his doctorate from the University of Texas in 1984 and trained as a postdoctoral fellow at Dana-Farber Cancer Institute and Harvard Medical School. Dr. Dionne is co-inventor on six issued United States patents and has co-authored more than 50 scientific publications.